FDA D.I.S.C.O. Burst Edition: FDA approval of Omisirge (omidubicel-onlv) to reduce time to neutrophil recovery and infection in patients with hematologic malignancies
0:00
3:30
Listen to a soundcast of the April 17, 2023, FDA approval of Omisirge (omidubicel-onlv) to reduce time to neutrophil recovery and infection in patients with hematologic malignancies.
Fler avsnitt från "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"
Missa inte ett avsnitt av “FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)” och prenumerera på det i GetPodcast-appen.